MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|HER2/Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Akt Inhibitor MK2206|PROCEDURE: Therapeutic Conventional Surgery|OTHER: Pharmacological Study|OTHER: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)